Literature DB >> 7559482

High activity suppression of myeloid progenitor proliferation by chimeric mutants of interleukin 8 and platelet factor 4.

T J Daly1, G J LaRosa, S Dolich, T E Maione, S Cooper, H E Broxmeyer.   

Abstract

The proliferation of human myeloid progenitor cells is negatively regulated in the presence of certain members of the chemokine family of molecules. This includes interleukin 8 (IL-8) and platelet factor 4 (PF4), which in combination are able to synergize, resulting in cell suppression at very low concentrations of these molecules. A series of PF4 and IL-8 mutant proteins were analyzed in an in vitro colony formation assay for myeloid progenitor cells to assess domains of these proteins that are required for activity. Mutation of either of the two DLQ motifs within PF4 resulted in an inactive protein. Perturbations within the IL-8 dimer interface region also resulted in mutants that were incapable of suppressing colony formation. A class of chimeric mutants consisting of domains of either PF4 and IL-8, Gro-alpha and PF4, or Gro-beta and PF4 were observed to inhibit myeloid cell proliferation at concentrations which were between 500- and 5000-fold lower than either the IL-8 or PF4 wild-type proteins alone. These chimeric mutants possessed activities that were comparable to or better than the activity observed when IL-8 and PF4 were added together in vitro. One of these highly active chimeric proteins was observed to be 1000-fold more active than either IL-8 or PF4 alone in suppressing not only the proliferation but also the cell cycling of myeloid progenitor cells following intravenous injection of the mutant into mice. Examination of additional IL-8-based mutants in the colony formation assay, which centered on the perturbation of the amino-terminal "ELR" motif, resulted in the observation that the highly active IL-8 mutant required both aspartic acid at amino acid residue 4 and either glutamine or asparagine at residue 6. Single mutations at either of these positions resulted in mutants with myelosuppressive activity equivalent to wild-type IL-8. Mutants such as IL-8M1 and IL-8M10 were observed to be significantly reduced in their ability to activate isolated human neutrophils, suggesting that separate mechanisms may exist by which myeloid progenitor cells and neutrophils are affected by chemokines.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7559482     DOI: 10.1074/jbc.270.40.23282

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

Review 1.  Regulation of hematopoiesis by chemokine family members.

Authors:  H E Broxmeyer
Journal:  Int J Hematol       Date:  2001-07       Impact factor: 2.490

2.  Growth factors/chemokines in diabetic vitreous and aqueous alter the function of bone marrow-derived progenitor (CD34⁺) cells in humans.

Authors:  Sankarathi Balaiya; Maria B Grant; Joshua Priluck; Kakarla V Chalam
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-08-26       Impact factor: 4.310

3.  Secreted nuclear protein DEK regulates hematopoiesis through CXCR2 signaling.

Authors:  Maegan L Capitano; Nirit Mor-Vaknin; Anjan K Saha; Scott Cooper; Maureen Legendre; Haihong Guo; Rafael Contreras-Galindo; Ferdinand Kappes; Maureen A Sartor; Christopher T Lee; Xinxin Huang; David M Markovitz; Hal E Broxmeyer
Journal:  J Clin Invest       Date:  2019-05-20       Impact factor: 14.808

4.  Solution NMR characterization of WT CXCL8 monomer and dimer binding to CXCR1 N-terminal domain.

Authors:  Prem Raj B Joseph; Krishna Rajarathnam
Journal:  Protein Sci       Date:  2014-11-28       Impact factor: 6.725

5.  IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells.

Authors:  Carolina Schinke; Orsolya Giricz; Weijuan Li; Aditi Shastri; Shanisha Gordon; Laura Barreyro; Laura Barreryo; Tushar Bhagat; Sanchari Bhattacharyya; Nandini Ramachandra; Matthias Bartenstein; Andrea Pellagatti; Jacqueline Boultwood; Amittha Wickrema; Yiting Yu; Britta Will; Sheng Wei; Ulrich Steidl; Amit Verma
Journal:  Blood       Date:  2015-03-25       Impact factor: 22.113

6.  The dynamics of interleukin-8 and its interaction with human CXC receptor I peptide.

Authors:  Agnieszka A Kendrick; Michael J Holliday; Nancy G Isern; Fengli Zhang; Carlo Camilloni; Chi Huynh; Michele Vendruscolo; Geoffrey Armstrong; Elan Z Eisenmesser
Journal:  Protein Sci       Date:  2014-02-12       Impact factor: 6.725

7.  Crystal structure of a human aminoacyl-tRNA synthetase cytokine.

Authors:  Xiang-Lei Yang; Robert J Skene; Duncan E McRee; Paul Schimmel
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-11       Impact factor: 11.205

Review 8.  Is interleukin 17, an inducible cytokine that stimulates production of other cytokines, merely a redundant player in a sea of other biomolecules?

Authors:  H E Broxmeyer
Journal:  J Exp Med       Date:  1996-06-01       Impact factor: 14.307

9.  Modulation of Hematopoietic Chemokine Effects In Vitro and In Vivo by DPP-4/CD26.

Authors:  Hal E Broxmeyer; Maegan Capitano; Timothy B Campbell; Giao Hangoc; Scott Cooper
Journal:  Stem Cells Dev       Date:  2016-03-30       Impact factor: 3.272

10.  Involvement of Interleukin (IL) 8 receptor in negative regulation of myeloid progenitor cells in vivo: evidence from mice lacking the murine IL-8 receptor homologue.

Authors:  H E Broxmeyer; S Cooper; G Cacalano; N L Hague; E Bailish; M W Moore
Journal:  J Exp Med       Date:  1996-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.